Business Context and Reporting Period
This Form 8-K filing by NanoViricides, Inc. reports a material definitive agreement entered into on July 11, 2018. The filing details an extension of the employment agreement with Dr. Anil R. Diwan, effective July 1, 2018, in his capacity as President of the Company.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
- Annual Base Salary: $400,000
- Immediate Incentive Award: $75,000 (payable prior to July 31, 2018)
- Equity Grant: 225,000 shares of Series A Preferred Shares
- Term Life Insurance: $2 million policy ($1 million assigned to the Company, $1 million to the estate)
- Severance Provision: Six months' salary if terminated without cause
Material Changes
The primary material change is the formalization of Dr. Diwan's compensation package and the grant of equity. The 225,000 Series A Preferred Shares are subject to a vesting schedule in one-third increments on June 30, 2019, June 30, 2020, and June 30, 2021.
Outlook, Risks, and Management Commentary
Management commentary is limited to the rationale for the agreement, citing the need to provide "leadership authority" and an "incentive towards the ultimate success of the Company." The filing does not contain forward-looking guidance, risk factors, or discussion of contingencies beyond the standard severance terms.
Investor Verification Checklist
- Verify the current market value and voting rights of the 225,000 Series A Preferred Shares granted.
- Confirm the Company's cash position to ensure it can meet the immediate $75,000 incentive award and ongoing salary obligations.
- Review the full text of the Employment Agreement (Exhibit 10.1) for any additional covenants or performance conditions not summarized here.
- Assess the impact of the equity grant on existing shareholder dilution.